Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Combining GITR inhibitors with immunotherapy in advanced cancers

Omid Hamid • 5 Jun 2023
ASCO 2023
General Antibodies Checkpoint Inhibitors INCAGN01876

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, provides an overview of a Phase I/II trial (NCT03126110) of INCAGN01876, a GITR inhibitor, with PD-1 and CTLA-4 inhibitors in patients with advanced cancers. Preliminary efficacy was observed in patients and no novel toxicities and adverse events were seen. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Omid Hamid

1:54
C-144-01: lifileucel in mucosal melanoma pretreated with ICIs
Omid Hamid • 23 Oct 2023
2:31
The future of BiTEs and ImmTACs in melanoma and beyond
Omid Hamid • 23 Oct 2023
1:55
The benefits of tebentafusp in uveal melanoma
Omid Hamid • 23 Oct 2023
2:01
Elucidating biomarkers of response in the RELATIVITY-047 trial
Omid Hamid • 23 Oct 2023

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals